| Title |
Statins and risk of breast cancer recurrence
|
|---|---|
| Published in |
Breast cancer targets and therapy, November 2016
|
| DOI | 10.2147/bctt.s116694 |
| Pubmed ID | |
| Authors |
Minas Sakellakis, Karolina Akinosoglou, Anastasia Kostaki, Despina Spyropoulou, Angelos Koutras |
| Abstract |
The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, P=0.006). Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 33% |
| Canada | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 18% |
| Student > Master | 5 | 15% |
| Researcher | 4 | 12% |
| Student > Ph. D. Student | 4 | 12% |
| Student > Doctoral Student | 3 | 9% |
| Other | 6 | 18% |
| Unknown | 6 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 35% |
| Biochemistry, Genetics and Molecular Biology | 5 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 12% |
| Agricultural and Biological Sciences | 2 | 6% |
| Immunology and Microbiology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 7 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2023.
All research outputs
#4,167,683
of 25,371,288 outputs
Outputs from Breast cancer targets and therapy
#56
of 324 outputs
Outputs of similar age
#64,072
of 317,794 outputs
Outputs of similar age from Breast cancer targets and therapy
#3
of 8 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,794 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.